Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989784 | 0.84 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6404270 | 0.84 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4452755 | 0.84 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL17208360 | 0.84 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL15786204 | 0.82 | TSHR (0.39) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL31402184 | 0.82 | CA1 (0.59) | CYP1A2 | |
| SCHEMBL20877749 | 0.82 | CA1 (0.59) | CYP1A2 | |
| SCHEMBL22246440 | 0.81 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL13356642 | 0.81 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1405629 | 0.81 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014086751-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYLOALKENYL ETHYNYL)-CYCLOHEXANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086723-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYLOALKENYL ETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-06-12 | — | — | WO | disclosed |
| US-20090124820-A1 | C1-Symmetric Bisphospine Ligands and Their Use in the Asymmetric Synthesis of Pregabalin | PFIZER INC. | 2009-05-14 | — | — | US | disclosed |
| EP-1727620-B1 | C1-SYMMETRIC BISPHOSPHINE LIGANDS AND THEIR USE IN THE ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER LAMBERT CO (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1727620-A1 | C1-SYMMETRIC BISPHOSPHINE LIGANDS AND THEIR USE IN THE ASYMMETRIC SYNTHESIS OF PREGABALIN | Warner-Lambert Company LLC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050228190-A1 | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin | BAO JIAN | 2005-10-13 | — | — | US | disclosed |
| WO-2005087370-A1 | C1-SYMMETRIC BISPHOSPHINE LIGANDS AND THEIR USE IN THE ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-22 | — | — | WO | disclosed |
| US-6399787-B1 | TRANSITION METAL COMPLEX | PENN STATE RESEARCH FOUNDATION | 2002-06-04 | — | — | US | disclosed |
| WO-1999059721-A1 | CATALYTIC ASYMMETRIC HYDROGENATION, HYDROFORMYLATION, AND HYDROVINYLATION VIA TRANSITION METAL CATALYSTS WITH PHOSPHINES AND PHOSPHITES | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228190-A1 | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin | GABRA5, CNR1, GABRE | MGAM 1482/4885GAA 3774/4885SI 1222/4885 |
| US-20090124820-A1 | C1-Symmetric Bisphospine Ligands and Their Use in the Asymmetric Synthesis of Pregabalin | GABRE, GABRP, GABRA5 | MGAM 2166/4885GAA 4104/4885SI 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.